Oslo, 30 April 2024 - Observe Medical ASA ("the Company" or "Observe Medical") today announces that the Company has published its Annual Report for 2023. The Annual Report was approved by the Board of Directors on 26 April 2024.

"Despite some challenges, 2023 was a year of great achievements and exciting opportunities. I am grateful for the dedication of the Observe Medical team and the continued support of our shareholders. Our ambition and goals for the future remain unchanged, and I look forward to updating you on our progress soon" commented Jørgen Mann, Interim CEO of Observe Medical.

The Annual Report for 2023 is attached to this notice and available on the Company's website under the Investor Relations section. The auditor's report, which is incorporated in the annual report, includes a statutory emphasis of matter relating to the further financing of the Company.

For further information, please contact:

Jørgen Mann, Interim CEO Observe Medical
Mobile: +45 408 67 558
E-mail: jorgen.mann@observemedical.com

Johan Fagerli, Interim CFO Observe Medical
Mobile: +47 958 12 765
E-mail: johan.fagerli@observemedical.com

About Observe Medical

Observe Medical is a Nordic medtech company that develops, markets and sells innovative medtech products for the global market. The Company is committed to improving patient welfare and patient outcomes, improving clinical data accuracy and promoting positive health economics.

The Company seeks to drive growth by leveraging its expertise in sales and commercialization of its broad portfolio of medical technology products, mainly in urine measurement, ultrasound, anesthesiology/ICUs, surgery and wound care, in combination with targeted M&A.

The Company is headquartered in Oslo, Norway, with additional offices in Narvik, Norway and Gothenburg, Sweden, and subsidiaries in Finland and the US. In addition, Observe Medical has a direct sale organization in the Nordics and a distributor network internationally.

Further information is available at www.observemedical.com.




(c) 2024 Cision. All rights reserved., source Press Releases - English